Assoc.Prof.Priv.Doz.Dr. Petra Obexer

group leader: Pediatric Oncology

list of publications

BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma

Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ

Oncogene 6 Jul 2015; (). [Epub ahead of print]

C10ORF10/DEPP, a transcriptional target of FOXO3, regulates ROS-sensitivity in human neuroblastoma.

Salcher S, Hagenbuchner J, Geiger K, Seiter MA, Rainer J, Kofler R, Hermann M, Kiechl-Kohlendorfer U, Ausserlechner MJ, Obexer P.

Mol Cancer. 1 Sep 2014; 13()224.

X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy.

Obexer P, Ausserlechner MJ

Front Oncol 28 Jul 2014; 4()659-71.

Discovery of Sanggenon G as a natural cell-permeable small-molecular weight inhibitor of X-linked inhibitor of apoptosis protein (XIAP).

Seiter MA, Salcher S, Rupp M, Hagenbuchner J, Kiechl-Kohlendorfer U, Mortier J, Wolber G, Rollinger JM, Obexer P, Ausserlechner MJ.

FEBS Open Bio 5 Jul 2014; 4()659-71.

BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery

Hagenbuchner J, Kuznetsov AV, Obexer P, Ausserlechner MJ

Oncogene 1 Oct 2013; 32(40)4748-57.

A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration.

Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ

Oncotarget 1 Aug 2013; 4(8)1241-52.

Therapy-resistant acute lymphoblastic leukemia (ALL) cells inactivate FOXO3 to escape apoptosis induction by TRAIL and Noxa.

Ausserlechner MJ, Salvador C, Deutschmann A, Bodner M, Viola G, Bortolozzi R, Basso G, Hagenbuchner J, Obexer P

Oncotarget 1 Jul 2013; 4(7)995-1007.

FOXO3/FKHRL1 is activated by 5-Aza-2-deoxycytidine (5-azadC) and induces silenced Caspase-8 in neuroblastoma.

Geiger, K.*, Hagenbuchner, J.*, Rupp, M., Fiegl, H., Sergi, C., Meister, B., Kiechl-Kohlendorfer, U., Müller, T., Ausserlechner, M.J.and Obexer, P.

1 Apr 2012; ().

FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3.

Hagenbuchner J, Kuznetsov A, Hermann M, Hausott B, Obexer P, Ausserlechner MJ.

J Cell Sci. 20 Feb 2012; 125(5)1191-203.

FOXO transcription factors as potential therapeutic targets in neuroblastoma

Ausserlechner, M. J., J. Hagenbuchner, S. Fuchs, K. Geiger, and P. Obexer.

In H. Shimada [ed.], Neuroblastoma - Present and Future 1 Jan 2011; ()325-348.

p16INK4A - connecting cell cycle control to cell death regulation in human leukemia, pp.

Obexer, P., J. Hagenbuchner, M. Holzner, and M. J. Ausserlechner

In O. Babusikova, S. Dovat, and K. S. Payne [eds.], T-cell Leukemia. 1 Jan 2011; ().

Toll-like Receptor-9 expression in breast and ovarian cancer is associated with poorly differentiated tumors.

Berger, R., Fiegl, H., Goebel, G., Obexer, P., Ausserlechner, MJ., Doppler, W., Hauser-Kronberger, C., Reitsamer, R., Egle, D., Reimer, D., Müller-Holzner, E., Jones, A., Widschwendter, M.

Cancer Sci. 1 Apr 2010; 101(4)1059-66.

The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.

Hagenbuchner J, Ausserlechner MJ, Porto V, David R, Meister B, Bodner M, Villunger A, Geiger K, Obexer P.

J Biol Chem. 5 Mar 2010; 285(10)6904-12.

p16INK4A sensitizes human leukemia cells to FAS- and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2

Obexer P, Hagenbuchner J, Rupp M, Salvador C, Holzner M, Deutsch M, Porto V, Kofler R, Unterkircher T, Ausserlechner MJ.

J Biol Chem. 6 Nov 2009; 284(45)30933-40.

Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.

Obexer P, Hagenbuchner J, Unterkircher T, Sachsenmaier N, Seifarth C, Böck G, Porto V, Geiger K, Ausserlechner M.

Mol Biol Cell 1 May 2009; 20(7)2041-8.

Endothelial cells from cord blood CD133(+)CD34(+) progenitors share phenotypic, functional and gene expression profile similarities with lymphatics.

Nguyen VA, Fürhapter C, Obexer P, Stössel H, Romani N, Sepp N.

J Cell Mol Med. 9 Apr 2008; (). [Epub ahead of print]Click here to read

FKHRL1- mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells.

Obexer P, Geiger K, Ambros PF, Meister B, Ausserlechner MJ.

Cell Death Differ. 1 Mar 2007; 14(3)534-47.

A retroviral expression system based on tetracycline-regulated tricistronic transactivator/repressor vectors for functional analyses of antiproliferative and toxic genes.

Ausserlechner MJ, Obexer P, Deutschmann A, Geiger K, Kofler R.

Mol Cancer Ther. 1 Aug 2006; 5(8)1927-34.

G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.

Ausserlechner MJ, Obexer P, Geley S, Kofler R.

Leukemia. 1 Jun 2005; 19(6)1051-7.

Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.

Hainz U, Obexer P, Winkler C, Sedlmayr P, Takikawa O, Greinix H, Lawitschka A, Potschger U, Fuchs D, Ladisch S, Heitger A.

Blood. 15 May 2005; 105(10)4127-34. Epub 2005 Jan 27

Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells.

Ausserlechner MJ, Obexer P, Bock G, Geley S, Kofler R.

Cell Death Differ. 1 Feb 2004; 11(2)165-74.

Defective T-helper cell function after T-cell-depleting therapy affecting naive and memory populations.

Heitger A, Winklehner P, Obexer P, Eder J, Zelle-Rieser C, Kropshofer G, Thurnher M, Holter W.

Blood 1 Jun 2002; 99(11)4053-62.

The cell cycle inhibitor p16(INK4A) sensitizes lymphoblastic leukemia cells to apoptosis by physiologic glucocorticoid levels.

Ausserlechner MJ, Obexer P, Wiegers GJ, Hartmann BL, Geley S, Kofler R.

J Biol Chem. 15 Jun 2001; 276(24)10984-9.

Interaction of HSV-1 infected peripheral blood mononuclear cells with cultured dermal microvascular endothelial cells: a potential model for the pathogenesis of HSV-1 induced erythema multiforme.

Larcher C, Gasser A, Hattmannstorfer R, Obexer P, Fürhapter C, Fritsch P, Sepp N.

J Invest Dermatol. 1 Jan 2001; 116(1)150-6.